1,028 reports of this reaction
2.3% of all AFLIBERCEPT reports
#12 most reported adverse reaction
BLINDNESS TRANSIENT is the #12 most commonly reported adverse reaction for AFLIBERCEPT, manufactured by Regeneron Pharmaceuticals, Inc.. There are 1,028 FDA adverse event reports linking AFLIBERCEPT to BLINDNESS TRANSIENT. This represents approximately 2.3% of all 43,844 adverse event reports for this drug.
Patients taking AFLIBERCEPT who experience blindness transient should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BLINDNESS TRANSIENT is a less commonly reported adverse event for AFLIBERCEPT, but still significant enough to appear in the safety profile.
In addition to blindness transient, the following adverse reactions have been reported for AFLIBERCEPT:
The following drugs have also been linked to blindness transient in FDA adverse event reports:
BLINDNESS TRANSIENT has been reported as an adverse event in 1,028 FDA reports for AFLIBERCEPT. This does not prove causation, but indicates an association observed in post-market surveillance data.
BLINDNESS TRANSIENT accounts for approximately 2.3% of all adverse event reports for AFLIBERCEPT, making it a notable side effect.
If you experience blindness transient while taking AFLIBERCEPT, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.